<DOC>
	<DOCNO>NCT01054014</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics ( drug absorb body , distribute within body remove body time ) single multiple dos JNJ-40346527 healthy volunteer . This study also investigate pharmacokinetics JNJ-40346527 without food .</brief_summary>
	<brief_title>A Single Multiple Dose Study Explore Safety Of JNJ-40346527 In Healthy Volunteers</brief_title>
	<detailed_description>JNJ-40346527 experimental drug test see may useful treat rheumatoid arthritis inflammatory disease . This study compare effect ( good bad ) JNJ-40346527 placebo ( look like drug study active ingredient ) healthy volunteer . This study first study JNJ-40346527 give human . This study conduct three part . Parts 1 2 randomize ( study drug assign chance ) , double-blind ( neither physician volunteer know identity assign drug ) study compare safety tolerability JNJ-40346527 placebo 96 healthy volunteer . Part 3 open-label ( people involve know identity assign drug ) , 2-period crossover ( mean volunteer receive treatment different time ) study effect food JNJ-40346527 8 healthy male volunteer . For Part 1 , participation period maximum 64 day , include screen visit , 5-day in-clinic period three follow-up visit . For Part 2 , participation period maximum 83 day , include screen visit , 18-day in-clinic period two follow-up visit . For Part 3 , participation period maximum 59 day , include screen visit , two 4-day in-clinic period separate 7 day break , follow-up visit . For three part study , safety evaluation , include ECG ( cardiac function test ) , vital sign monitor side-effects perform . Additionally , blood urine sample collect evaluation . Volunteers participate 1 3 part ; Part 1 : volunteer receive single oral ( mouth ) dose JNJ-40346527 ( 10 , 50 , 150 , 300 , 600 , 1000mg ) placebo ; Part 2 : volunteer receive oral dos JNJ-40346527 ( 50 , 150 , 300 , 500 750mg ) placebo day 14 day ; Part 3 : volunteer receive two oral dos 150mg JNJ-40346527 without food , 7-day break dos .</detailed_description>
	<criteria>Must generally good health Have negative result HIV , hepatitis B , hepatitis C Nonsmoker least 6 month Females must non childbearing potential , i.e. , either : surgically sterile ( bilateral tubal ligation removal ovary and/or uterus partial hysterectomy least 6 month prior dose ) , naturally postmenopausal least 2 year , negative blood urine pregnancy test prior dose must consent use medically acceptable method contraception throughout entire study period 90 day study complete History alcohol drug abuse Average consumption 5 cup caffeinated beverage ( tea/coffee/cocoa/cola ) per day History type significant allergy ( eg , anaphylaxis , prominent respiratory skin symptom ) Use St.John 's Wort ( hypericin ) 30 day first dose Use type hormone replacement therapy 30 day first dose history receive live virus vaccination within past month plan receive vaccination live virus vaccine within 2 week follow last dose medication receipt experimental drug medical device within last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>CR016795</keyword>
</DOC>